Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapyDan P. Zandberg, Ricard Mesı́a, Antonio Jimeno et al.|European Journal of Cancer|2018Cited by 267